Mersana Therapeutics shares are trading lower after the FDA issued a partial clinical hold pausing new patient enrollment in the company's UP-NEXT and UPGRADE-A ovarian cancer trials.
Portfolio Pulse from Benzinga Newsdesk
Mersana Therapeutics' shares are trading lower after the FDA issued a partial clinical hold, pausing new patient enrollment in the company's UP-NEXT and UPGRADE-A ovarian cancer trials.
June 15, 2023 | 11:49 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mersana Therapeutics' stock price is likely to be negatively impacted by the FDA's partial clinical hold on new patient enrollment in its ovarian cancer trials.
The FDA's partial clinical hold on Mersana Therapeutics' UP-NEXT and UPGRADE-A ovarian cancer trials directly affects the company's ongoing research and development efforts. This regulatory action is likely to cause uncertainty among investors, leading to a negative impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100